Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals reported a robust Q3 FY25, with revenue from operations growing 18% year-on-year to INR 1,963 crores. Adjusted PAT saw a significant increase of 43% year-on-year, reaching INR 171 crores. EBITDA, excluding other income, grew 23% year-on-year to INR 362 crores, maintaining a healthy margin of 18.4%. Gross margins for the quarter stood at 60.1%, a slight decline from 62.7% in Q3 FY24, attributed to business mix including lower-margin Sanofi products.

The domestic business grew 12% year-on-year to INR 888 crores. However, organic growth excluding FCM (Fixed Cost Management) issues was around 4%, with FCM impacting reported growth by approximately 3%. The company restructured its cardio-diabetos portfolio by integrating Sanofi products and personnel, which temporarily impacted sales traction in the current quarter. Management expects to see improvement in domestic cardiac segment growth from Q4 FY25 onwards as products stabilize in new divisions.

International markets demonstrated strong growth, increasing 23% to INR 1,075 crores. This was primarily driven by Canada, which grew 34% to INR 352 crores, benefiting from the full integration of the Mantra acquisition. Emerging markets also saw significant growth of 40% to INR 365 crores, led by non-ARV segments. Europe, however, experienced muted growth at 2% to INR 358 crores, but is expected to return to high single-digit growth in FY26.

Emcure is actively expanding into new therapeutic areas. The Derma subsidiary, Emcutix, is now fully operational with a team of over 200, planning new in-house and partner product launches from FY26, targeting prescription Derma, cosmeceuticals, and eventually OTC. In Ophthalmology, the company is pursuing on-label approval for Bevacizumab for wet AMD in India, leveraging its patented device and sterile product expertise to ensure better patient compliance and ease of use, differentiating from existing off-label uses.

The company is making significant strides in its product pipeline, particularly with Liposomal Amphotericin B, which is seeing approvals flow through in target markets. Emcure is also on the verge of getting recombinant Asparaginase cleared and is confident about being in the first wave of Semaglutide launches in India by March 2026. The strategy for Semaglutide emphasizes vertical integration, including API and formulation, and leveraging its trained field force for scientific detailing.

Emcure aims for a 300-400 basis points improvement in its margin profile over the next 3-4 years, driven by operating leverage and better productivity from new facilities. The company's net debt reduced to INR 600 crores at quarter-end from INR 705 crores in Q2, with gross debt at INR 800 crores and cash at INR 200 crores. Management anticipates becoming debt-free within the next two to three quarters through internal cash flow generation, barring any major M&A activities.